Interleukin‐6/<scp>STAT</scp>3 signaling as a promising target to improve the efficacy of cancer immunotherapyHidemitsu Kitamura, Akinobu Taketomi, Norihiko Takahashi et al.|Cancer Science|2017Cited by 295
IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cellsYosuke Ohno, Akinobu Taketomi, Hidemitsu Kitamura et al.|Cancer Immunology Immunotherapy|2016Cited by 116
IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signalling pathwayKentaro Sumida, Hidemitsu Kitamura, Yosuke Ohno et al.|Scientific Reports|2015Cited by 31